Devonian Health Group is trading 8.82% down at CA$7.75 as investors appeared to reassess its proposed NYSE American listing and concurrent underwritten offering.
- The financing could increase share supply and dilute existing holders, weighing on the stock after its late-July rally.
- The broader biotech sector is rising, so sector weakness does not explain today’s decline.